Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

LungLife AI Inc

9H4:FRA

LungLife AI Inc

Actions
  • Price (EUR)0.099
  • Today's Change0.001 / 0.51%
  • Shares traded600.00
  • 1 Year change-88.88%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 08:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.

  • Revenue in GBP (TTM)23.08k
  • Net income in GBP-3.55m
  • Incorporated2009
  • Employees15.00
  • Location
    LungLife AI Inc2545 W. Hillcrest Drive, Suite 140THOUSAND OAKS 91320United StatesUSA
  • Phone+1 (805) 409-9868
  • Fax+1 (805) 855-2003
  • Websitehttps://lunglifeai.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.